Navalign LLC Has $409,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Navalign LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 44.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,221 shares of the biopharmaceutical company’s stock after selling 11,327 shares during the period. Navalign LLC’s holdings in Pfizer were worth $409,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. RB Capital Management LLC boosted its position in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. boosted its position in shares of Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after buying an additional 400 shares in the last quarter. United Bank boosted its holdings in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the period. Ergoteles LLC increased its holdings in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp lifted its holdings in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.1 %

PFE stock traded down $0.03 during trading on Thursday, reaching $27.75. 39,620,254 shares of the stock traded hands, compared to its average volume of 43,835,094. The business’s 50 day moving average price is $27.46 and its 200-day moving average price is $29.46. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market capitalization of $157.14 billion, a PE ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 earnings per share. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. Truist Financial lowered their price target on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 14th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. UBS Group dropped their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Friday, March 1st. Finally, Barclays decreased their price objective on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.